Sort
21,453 grants matching “tuberculosis”
Mechanisms of increased susceptibility to pulmonary Nontuberculous Mycobacterial disease in the elderly
$712,458Ilhem Messaoudi · University Of Kentucky · R01 · FY2022 · AI
Mechanisms of increased susceptibility to pulmonary Nontuberculous Mycobacterial disease in the elderly
$712,457Ilhem Messaoudi · University Of Kentucky · R01 · FY2023 · AI
IMPACT OF TUBERCULOSIS OF HIV INFECTION IN UGANDA
$712,293Case Western Reserve University · R01 · FY2001 · AI
Mycobacterium tuberculosis disease effect on HIV-1 immunity, evolution, and persistence
$711,993Manish Sagar · Boston Medical Center · R56 · FY2025 · AI
When are in-person HIV services worth the risk of COVID-19 and other communicable illnesses? Optimizing choices when virtual services are less effective
$711,920Anna Bershteyn · New York University School Of Medicine · R01 · FY2024 · MH
Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial
$711,595Christina Yoon · University Of California, San Francisco · R33 · FY2024 · HL
Identifying individuals at risk of progression to active tuberculosis
$711,592Antonino None Catanzaro · University Of California, San Diego · R01 · FY2020 · AI
Lethal action of fluoroquinolones with non-growing Mycobacterium tuberculosis
$711,506Karl A Drlica · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2007 · AI
Transmission of HIV-Associated XDR TB in Rural South Africa
$711,468Neel Rajnikant Gandhi · Emory University · R01 · FY2014 · AI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis
$711,432David R Sherman · University Of Washington · R01 · FY2024 · AI
Necrosis in pulmonary TB granulomas: dynamics, mechanisms, therapies
$711,270Igor Kramnik · Boston University Medical Campus · R01 · FY2017 · HL
Predicting protective T-cell responses in Tuberculosis using a systems biology approach
$711,246Denise E Kirschner · University Of Michigan At Ann Arbor · R01 · FY2019 · AI
TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
$711,208University Of California Los Angeles · R01 · FY2000 · DA
Multifunctional nanoparticles for enhanced drug delivery to the lung
$711,169Hugh David Smyth · University Of Texas At Austin · R33 · FY2012 · HL
CAfGEN Administrative Centre
$711,099Mogomotsi Sandy Matshaba · Botswana Baylor Child/Clincal Ctr/Excell · U54 · FY2020 · AI
Hybrid trial for Alcohol reduction among people with TB and HIV in India (HATHI)
$710,982Amita Gupta · Johns Hopkins University · R01 · FY2024 · AA
Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting
$710,894Sarit A Golub · Hunter College · R01 · FY2012 · AA
SOC Core
$710,811Aleksandar Milosavljevic · Baylor College Of Medicine · U54 · FY2013 · DA
HIV, gestational diabetes and TB in pregnancy
$710,775Jyoti S Mathad · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AI
Epidemiology of coronary artery disease among people with HIV in rural sub-Saharan Africa
$710,755Mark J Siedner · Massachusetts General Hospital · R01 · FY2019 · HL
Aerosol spectinamide-1599 therapy against tuberculosis
$710,674Mercedes Gonzalez-Juarrero · Colorado State University · R01 · FY2020 · AI
Mycobacterial Genes, Antigens, and Vaccines
$710,304Harvard University (Sch Of Public Hlth) · R01 · FY2004 · AI
Admin Core
$710,234Samithamby Jeyaseelan · Louisiana State Univ A&M Col Baton Rouge · P20 · FY2023 · GM
Deep sequencing of pathogens to precisely define transmission networks using rare variants
$710,065William Hanage · Harvard School Of Public Health · R01 · FY2019 · AI
Development and Testing of New Tuberculosis Vaccines
$709,646Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2009 · AI